CAD 0.05
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -8.13 Million CAD | -54.46% |
2022 | -4.56 Million CAD | -131.11% |
2021 | -2.06 Million CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -589.66 Thousand CAD | 69.69% |
2024 Q2 | -991.4 Thousand CAD | -68.17% |
2023 Q2 | -1.77 Million CAD | -132.06% |
2023 FY | - CAD | -54.46% |
2023 Q4 | -1.54 Million CAD | -19.05% |
2023 Q3 | -1.3 Million CAD | 26.56% |
2023 Q1 | -763.28 Thousand CAD | 16.0% |
2022 Q2 | -1.18 Million CAD | 4.16% |
2022 Q1 | -1.23 Million CAD | -28.81% |
2022 Q4 | -908.62 Thousand CAD | -9.94% |
2022 FY | - CAD | -131.11% |
2022 Q3 | -826.5 Thousand CAD | 30.37% |
2021 Q1 | -92.05 Thousand CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q3 | -222.4 Thousand CAD | -127.13% |
2021 Q4 | -961.48 Thousand CAD | -332.32% |
2021 Q2 | -97.91 Thousand CAD | -6.36% |
2020 FY | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Algernon Pharmaceuticals Inc. | -4.98 Million CAD | -63.325% |
BetterLife Pharma Inc. | -3.19 Million CAD | -154.93% |
BioVaxys Technology Corp. | -7.68 Million CAD | -5.836% |
ChitogenX Inc. | -2.69 Million CAD | -202.004% |
Rapid Dose Therapeutics Corp. | -3.02 Million CAD | -168.981% |
Defence Therapeutics Inc. | -12.67 Million CAD | 35.815% |
Entheon Biomedical Corp. | 13.99 Thousand CAD | 58243.222% |
Gemina Laboratories Ltd. | -5.17 Million CAD | -57.192% |
Glow Lifetech Corp. | -1.26 Million CAD | -544.158% |
Lexston Life Sciences Corp. | -648.32 Thousand CAD | -1154.925% |
Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -1045.614% |
Doseology Sciences Inc. | -319.47 Thousand CAD | -2446.648% |
MYND Life Sciences Inc. | -1.82 Million CAD | -345.759% |
Nova Mentis Life Science Corp. | -1.2 Million CAD | -576.702% |
PharmaTher Holdings Ltd. | -3.04 Million CAD | -167.335% |
PreveCeutical Medical Inc. | -955.08 Thousand CAD | -751.857% |
Telescope Innovations Corp. | -5.49 Million CAD | -48.185% |